MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41591-026-04476-6

Медицинская библиотека · Nature medicine · 2026

Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.

Rosenstock Julio, Lingvay Ildiko, Ryan Donna, Jastreboff Ania M, Kushner Robert, Acosta Andres, Blevins Thomas C, Choi Melissa, Holmes Faith L, Smith Timothy, Connery Lisa, Li Yao, Liu Mike Ke, Barth Aline, Butcher Jamie, Civitarese Antonio, Yue Huibin, Coll Blai, ACCESS Trial Investigators

СтатьяРандомизированное исследованиеКлиническое исследование II фазыПеревод в очереди

Аннотация

Aleniglipron is an oral, small-molecule glucagon-like peptide-1 receptor agonist (GLP1-RA) in development for obesity treatment. The ACCESS phase 2b placebo-controlled, double-blind study randomized 230 adults (mean BMI 39.5 kg m-2, 54% female) with obesity or overweight to examine the effects of once-daily aleniglipron escalated every 4 weeks to 45, 90 or 120 mg. At week 36, the trial met its primary endpoint with a placebo-adjusted LS mean (95% confidence interval) body-weight change from baseline of -8.2% (-11.1 to -5.3%), -9.8% (-12.5 to -7.2%) and -11.3% (-13.9 to -8.6%) for the aleniglipron 45-, 90- and 120-mg arms, respectively (P < 0.0001, all doses versus placebo), with no apparent weight-loss plateau at the end of the double-blind period. Continued weight loss was observed at the interim analysis (median treatment duration of 20 weeks) of the ongoing open-label extension. Gastrointestinal events were generally mild to moderate and decreased in frequency over time, with little to no recurrence of vomiting after reintroduction following permitted dose interruptions. Treatment-related discontinuations were 10.4% across aleniglipron arms, with no events of drug-induced liver injury. Clinically relevant weight reductions of up to 11.3% with a tolerability profile consistent with the GLP-1RA class support further development of aleniglipron for obesity treatment. ClinicalTrials.gov registration: NCT06693843 .

Для цитирования: Rosenstock Julio, Lingvay Ildiko, Ryan Donna, Jastreboff Ania M, Kushner Robert, Acosta Andres, Blevins Thomas C, Choi Melissa, Holmes Faith L, Smith Timothy, Connery Lisa, Li Yao, Liu Mike Ke, Barth Aline, Butcher Jamie, Civitarese Antonio, Yue Huibin, Coll Blai, ACCESS Trial Investigators. Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.. Nature medicine. 2026. DOI: 10.1038/s41591-026-04476-6.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.